GP
ACAD icon

GLG Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

GLG Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$114K Buy
+3,794
New +$121K 0.01% 405

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

GLG Partners's ACAD Position: Q4 2017 in Review

GLG Partners opened a new position in Acadia Pharmaceuticals (ACAD) in Q4 2017: 3,794 shares worth $114K. The stake represents 0.01% of the portfolio and ranks #405 among its holdings.

210 funds tracked by Wall St. Rank hold ACAD as of Q4 2017.

  • GLG Partners held 3,794 shares of Acadia Pharmaceuticals worth $114K as of Q4 2017.
  • Acadia Pharmaceuticals was a new GLG Partners position in Q4 2017.
  • Acadia Pharmaceuticals made up 0.01% of GLG Partners's portfolio in Q4 2017, its #405 holding.
  • 210 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.